Pfizer's Failure Provides Clarity for ArQule

2010-09-11T18:11:24Z

...

Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)

2010-09-11T13:22:31Z

...

New lung cancer treatment shrinks some tumors: study

2010-06-05T12:15:50Z

A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday.

The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer (NSCLC) with a specific gene alteration of an enzyme implicated in cancer cell growth, known as anaplastic lymphoma kinase, or ALK.

According to Pfizer, ...

Lung cancer drug shows big promise in early tests

2010-06-05T07:45:13Z

Pfizer drug shows big promise in early testing for lung cancer patients with a certain gene

Doctors are reporting unusually high success rates from early tests of an experimental lung cancer drug.

The drug, called crizotinib, (crih-ZAH-tin-ib), is made by Pfizer Inc. It targets a gene that is found in about 4 percent of lung cancers, which amounts to 10,000 people a year in the

Anti-tumor impact seen with Pfizer lung cancer drug

2010-06-05T06:30:12Z

NEW YORK (Reuters) - An experimental drug being developed by Pfizer Inc that targets a specific gene mutation demonstrated impressive anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC), according to data from a small study presented on Saturday.

More than half of the patients treated with the drug, crizotinib, experienced significant ...

Pfizer Ends Study on Potential Lung Cancer Drug

2010-10-25T11:27:08Z

...

Pfizer Discontinues a Phase 3 Study of Figitumumab in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

2010-10-25T11:27:08Z

...

Pfizer ends late-stage lung-cancer study

2010-04-16T08:03:00Z

NEW YORK (Reuters) - Pfizer Inc said on Tuesday it has ended a late-stage lung cancer study of its experimental drug figitumumab after an analysis showed it was unlikely to meet the main goal of improving overall survival.

The analysis by an independent safety monitors found that adding figitumumab to two older therapies -- paclitaxel and carboplatin -- would be u...

Pfizer halts enrollment in lung cancer trial

2010-04-16T09:54:25Z

NEW YORK (Reuters) - Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday.

The halt was recommended by independent safety monitors overseeing the study. In their review, the monitors found more serious adverse events, including deaths, with patients receiv...

UPDATE 2-Pfizer halts enrollment in lung cancer trial

2010-10-22T07:47:13Z

...

Abbott, Pfizer in pact for lung cancer screening

2010-04-16T10:37:45Z

CHICAGO (Reuters) - An Abbott Laboratories Inc unit that makes genetic tests will work with Pfizer Inc to develop a test to screen non-small cell lung cancer (NSCLC) tumors to determine which patients are good candidates for a novel cancer therap...

Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008

2010-10-23T16:00:25Z

...

Mannkind: Overlooked Biotech With Excellent Prospects (Part II)

2010-10-21T08:56:57Z

...

New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma

2010-10-23T15:58:38Z

...

Pfizer Reviews Progress of Oncology Pipeline and New Commercial Business Unit Structure with Analysts

2010-10-23T15:58:38Z

...

Inhalable insulin prescribing information revised to include lung malignancy occurrence

2010-10-22T22:57:33Z

...

Pfizer Settlement

2010-04-02T22:51:46Z

FBI Assistant Director of Criminal Investigative Division Kevin Perkins, right, looks on as Associate Attorney General Tom Perrelli, answers questions during a news conference to announce Pfizer will pay a record $2.3 billion civil and c...

Pfizer CEO

2010-04-14T10:37:58Z

Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference Monday, Jan. 26, 2009, in New York. Eager to dispel doubts about the difficulties of executing Pfizer Inc.'s $68 billion tie-up with Wyeth, Pfizer's CEO said it will be done more like microsurgery than just stitching two huge corporations together. (AP Photo/Mark...

Pfizer to acquire Wyeth for $68 billion dollars

2010-04-18T13:01:49Z

epa01614571 Jeffery B. Kindler, Chairman and CEO of Pfizer (L) speaks as Bernard Poussot, Chairman and CEO of Wyeth listens at a press conference to announce that Pfizer will acquire Wyeth for approximately 8 billion dollars, at Pfizer headquarters in New York,

News on Pfizer Inc.